Skip to main content
. 2024 Jun 28;13(10):2105–2121. doi: 10.1007/s40121-024-01007-z

Fig. 3.

Fig. 3

Durability of response at 24 weeks among patients without recurrence through 8 weeks in patients who received at least one dose of VOS in ECOSPOR III and/or ECOSPOR IV. Among those patients with non-recurrence through week 8 (316/349; 90.5%), 93.7% (296/316) maintained a durable response through week 24